A Novel Approach to Discriminate Subgroups in Multiple Sclerosis.

Area of Science:

• Neuroimmunology
• Clinical Immunology
• Biomarker Discovery

Background:

• Multiple sclerosis (MS) is a central nervous system autoimmune disease involving diverse immune cells.
• Understanding immune cell activity is crucial for differentiating MS subtypes and developing targeted therapies.

Purpose of the Study:

• To evaluate serum levels of soluble CD4 (sCD4), sCD8, sCD163, and immunoglobulins (IgG, IgM, IgA).
• To assess these components as potential biomarkers for T-cells, macrophages, and B-cells activity in various MS types.
• To differentiate between relapsing-remitting MS (RRMS), primary progressive MS (PPMS), secondary progressive MS (SPMS), clinically isolated syndrome (CIS), and neuromyelitis optica (NMO).

Main Methods:

• Enzyme-linked immunosorbent assay (ELISA) was used to measure serum levels of sCD4, sCD8, and sCD163.
• Nephelometric technique determined serum levels of IgG, IgM, and IgA.
• Discriminant analysis was applied to identify significant classification functions based on immunological markers.

Main Results:

• Significant differences in serum levels of sCD4, sCD8, sCD163, IgG, IgM, and IgA were observed across the MS groups (p<0.05).
• Discriminant analysis identified four significant functions, with the primary function explaining 85.5% of the variance (correlation=0.79).
• Preliminary data indicate potential for differentiating MS types using sCD4, sCD163, IgM, and IgG levels.

Conclusions:

• Serum levels of sCD4, sCD8, sCD163, and immunoglobulins show significant variations among different MS subtypes.
• These immunological markers hold promise for discriminating between MS types, including RRMS, PPMS, SPMS, CIS, and NMO.
• Further research is needed to fully establish these markers for precise characterization of individual MS disease types.